This cohort study (2024) evaluates the diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. Results demonstrate the assay's efficacy in identifying Alzheimer disease, suggesting its potential as a reliable biomarker for early detection and diagnosis, thereby enhancing clinical decision-making.